{"url_path":"/sec/coya/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1835022/0001193125-26-218201-index.html","accession_number":"0001193125-26-218201","cik":"0001835022","ticker":"COYA","issuer_name":"Coya Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1835022/0001193125-26-218201-index.html","primary_entity_key":"0001835022","primary_entity_name":"Coya Therapeutics, Inc."},"word_count":57,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\n \n\nInsider Trading Arrangements and Policies\n\n \n\nDuring the quarter ended March 31, 2026, none of our directors or officers adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408, that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)."}